AMGEN INC AMGEN ORD (CDI) news, videos and press releases - Page 4
For more news please use our advanced search feature.
AMGEN INC AMGEN ORD (CDI) - More news...
AMGEN INC AMGEN ORD (CDI) - More news...
- AMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND
- AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA
- AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
- AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
- AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022
- AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE
- AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE
- AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
- AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
- NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
- AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
- AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
- AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
- AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
- AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS
- AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
- AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022
- AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS
- AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
- AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS
- AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE
- AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT
- AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
- AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
- AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS
- AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
- AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
- Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference
- AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
